Lifeline for mitochondrial patients: expanded access to vatiquinone opens
NCT ID NCT07159139
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This program offers continued access to the experimental drug vatiquinone for people with inherited mitochondrial diseases (like Leigh syndrome) who finished a previous safety study. It is not a cure, but aims to help manage the disease. Participants must have already been on the drug and cannot join another vatiquinone trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.